###begin article-title 0
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
Mutations of PIK3CA in gastric adenocarcinoma
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
###xml 472 481 468 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 310 315 <span type="species:ncbi:9606">human</span>
Activation of the phosphatidylinositol 3-kinase (PI3K) through mutational inactivation of PTEN tumour suppressor gene is common in diverse cancer types, but rarely reported in gastric cancer. Recently, mutations in PIK3CA, which encodes the p110alpha catalytic subunit of PI3K, have been identified in various human cancers, including 3 of 12 gastric cancers. Eighty percent of these reported mutations clustered within 2 regions involving the helical and kinase domains. In vitro study on one of the "hot-spot" mutants has demonstrated it as an activating mutation.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 34 41 34 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 159 166 159 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 205 212 205 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 429 435 429 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Based on these data, we initiated PIK3CA mutation screening in 94 human gastric cancers by direct sequencing of the gene regions in which 80% of all the known PIK3CA mutations were found. We also examined PIK3CA expression level by extracting data from the previous large-scale gene expression profiling study. Using Significance Analysis of Microarrays (SAM), we further searched for genes that show correlating expression with PIK3CA.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 297 304 297 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 378 380 378 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 488 494 488 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
We have identified PIK3CA mutations in 4 cases (4.3%), all involving the previously reported hotspots. Among these 4 cases, 3 tumours demonstrated microsatellite instability and 2 tumours harboured concurrent KRAS mutation. Data extracted from microarray studies showed an increased expression of PIK3CA in gastric cancers when compared with the non-neoplastic gastric mucosae (p < 0.001). SAM further identified 2910 genes whose expression levels were positively associated with that of PIK3CA.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
Our data suggested that activation of the PI3K signalling pathway in gastric cancer may be achieved through up-regulation or mutation of PIK3CA, in which the latter may be a consequence of mismatch repair deficiency.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 385 386 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 629 634 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 635 636 635 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 729 736 729 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 737 738 737 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 739 740 739 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 758 762 758 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AKT </italic>
###xml 771 772 771 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 773 774 773 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1070 1071 1070 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1382 1383 1382 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1384 1385 1384 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
The phosphatidylinositol 3-kinase (PI3K)-AKT signalling pathway is involved in the regulation of diverse cellular processes, including cell growth, survival and motility. Abnormal activation of this pathway is frequently observed in various cancer types, leading to aberrant cell cycle progression, altered adhesion and motility, inhibition of apoptosis and induction of angiogenesis [1]. It has been previously reported that genetic alterations involving various members along this signalling pathway could lead to its activation in cancer. These include mutation, allelic loss or promoter methylation of the negative regulator PTEN [2]; or alternatively, chromosomal amplification or over-expression of the positive regulators PIK3CA [3-5] and the various AKT kinases [6,7]. Furthermore, changes in other related pathways that are commonly altered in cancer, such as those involved in growth factor stimulation via the G-protein-coupled receptors or through direct interaction with the activated form of small GTPase RAS, can also lead to PI3K-AKT pathway activation [8]. Activation of this pathway results in the phosphorylation of AKT at Thr-308/309 and Ser-473/474. These phosphorylated forms of AKT proteins have been detected by Western blot or immunohistochemistry in various cancer types, suggesting the frequent activation of PI3K-AKT pathway in the carcinogenic process [7,9].
###end p 11
###begin p 12
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 619 624 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 841 846 841 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 902 907 902 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 981 986 981 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AKT1 </italic>
###xml 1040 1042 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1066 1073 1066 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 1151 1153 1151 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1179 1186 1179 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1250 1255 1250 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3K </italic>
###xml 1258 1262 1258 1262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3K</italic>
###xml 1324 1330 1324 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
###xml 1433 1440 1429 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 1823 1825 1819 1821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1909 1916 1905 1912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 1948 1955 1944 1951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 2080 2082 2076 2078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 2083 2085 2079 2081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 2150 2157 2146 2153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 1217 1222 <span type="species:ncbi:9606">human</span>
###xml 1875 1880 <span type="species:ncbi:9606">human</span>
Although genetic changes along the PI3K-AKT pathway have been repeatedly documented in brain, ovarian, endometrial, breast, prostate and thyroid cancers [1,2], reports on its mechanism of activation in gastric cancer are limited. Gastric cancer is the second most common cancer worldwide but its molecular basis of tumourigenesis is still poorly understood. Previous immunohistochemical study has demonstrated the presence of the phosphorylated form of AKT in 78% of gastric cancer [10], suggesting that activation of this pathway may also be common in gastric cancer. Though loss of heterozygosity (LOH) involving the PTEN locus has been demonstrated in 47% of gastric cancer in a recent study, mutation or promoter methylation was absent even in cases with LOH [11]. Thus data from this study could not support the two-hit inactivation of PTEN in gastric cancer, while the biological significance of PTEN haploinsufficiency remains controversial. Alternatively, amplification of AKT1 has been reported in a single case of gastric cancer [12], and amplification of PIK3CA associated with elevated mRNA levels has been found in 36% of gastric cancer [11]. More recently, Samuels et al. screened a diverse spectrum of human cancers for mutation in 16 PI3K or PI3K-like genes and found a high frequency of somatic mutation in PIK3CA, which encodes the p110alpha catalytic subunit. Major screening in colorectal cancer (CRC) identified PIK3CA mutations in 74 out of 234 (32%) cases, while mutations were also noted in 3 out of 12 (25%) gastric cancers. Reported mutations were mostly of missense type, and clustered within 2 regions in the helical and kinase domains. Expression of a "hot-spot" mutant, H1047R, conferred a significant up-regulation of lipid kinase activity of PIK3CA, suggesting it as an activating mutation [13]. In this study, we have examined a series of 94 human gastric adenocarcinomas for PIK3CA mutation. We have also examined PIK3CA expression level by extracting data from a large-scale gene expression profiling study previously performed for these cases [14,15]. Using SAM, genes with significant correlating expression with PIK3CA have also been identified.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient samples preparation
###end title 14
###begin p 15
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 570 575 570 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 879 881 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 882 884 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
DNA samples used for sequencing were prepared from frozen tumour and non-tumour gastric mucosae from 94 gastric cancer patients who underwent gastrectomy in the Department of Surgery, Queen Mary Hospital, The University of Hong Kong, as previously described [16]. Majority of the frozen samples (n = 81) showed tumour component of over 70%, whereas in 13 cases a lower proportion between 50 to 70% was accepted due to the tumours' inherent diffuse infiltrative nature with entrapment of non-neoplastic components. Analysis for microsatellite instability (MSI), BRAF and KRAS mutation have been performed and reported previously [16]. RNA preparation and gene expression profiling using a cDNA microarray containing 44,500 cDNA clones, representing around 30,300 unique genes, has been performed and reported in 90 of these tumours in comparison to 22 non-tumour gastric mucosae [14,15]. This study was approved by the Ethics Committee of the University of Hong Kong.
###end p 15
###begin title 16
Mutational screening
###end title 16
###begin p 17
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 217 224 217 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 271 278 271 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 437 454 437 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 888 892 879 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1262 1270 1251 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Explorer</italic>
Mutation screening of PIK3CA was performed for exons 9 and 20, covering the mutational hotspots; and for exon 18, from which a mutation was found in a gastric cancer. Mutations in these 3 exons constituted 80% of all PIK3CA mutations detected in the previous study [13]. PIK3CA intron-specific external amplification primers and internal sequencing primers were designed according to the previous study [13] with some modifications [see Additional file 1]. In particular, primers for exon 9 have been modified to avoid amplification of homologous sequences located in other chromosomes. PCR products were generated using the external primers and directly sequenced using the internal primers with the DYEnamictrade mark ET Terminator Cycle Sequencing Kit (Amersham Biosciences, Freiburg, Germany) according to the manufacturer's instruction. Electrophoresis was performed in the ABI Prism(R) 3700 DNA Analyzer (Applied Biosystems, Foster City, CA, USA). For each exon, PCR products were generated from 2 independent PCR reactions for sequencing of the forward and reverse strands. For exon 9, 2 independent PCR followed by sequencing of the forward strand were performed. Analysis of the chromatograms was performed using the mutation analysis software Mutation Explorertrade mark (SoftGenetics, State College, PA, USA).
###end p 17
###begin title 18
Extraction of expression data and statistical analysis
###end title 18
###begin p 19
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 409 416 409 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 495 502 495 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 629 630 629 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 718 725 718 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
Gene expression data were extracted from the microarray database containing 126 samples (90 gastric cancers, 14 lymph node metastasis and 22 non-tumour gastric mucosae) based on a 3-fold signal above background ratio for either channel and with 80% good data [14]. Gene expression data from 20,336 cDNA clones satisfied this selection criteria and were extracted, which included a cDNA clone corresponding to PIK3CA (IMAGE clone number 345430, GenBank accession no. W72473). Expression data for PIK3CA was extracted and the differences in expression levels between tumour and non-tumour tissues were examined using the Student's t-Test. SAM was performed to identify genes with significant correlating expression with PIK3CA [17]. The missing values in the dataset were estimated by a K-nearest neighbours impute algorithm using 10 nearest neighbour [18] followed by 5000 permutations in the SAM analysis.
###end p 19
###begin title 20
Results
###end title 20
###begin p 21
###xml 63 70 63 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Among the 94 gastric adenocarcinoma analysed, we have detected PIK3CA mutation in 4 cases. Two cases harboured the mutation A3140G (H1047R) in exon 20, and the other 2 cases with mutations G1624A (E542K) and G1633A (E545K) in exon 9. Representative sequence chromatograms are shown in figure 1. All four mutations were absent in the corresponding non-neoplastic mucosae and thus were confirmed as somatic mutations. Though the overall mutation frequency (4.3%) was lower than that of the previous study, the nature of the 4 mutations found were consistent with those identified at the reported hotspots. In particular, the H1047R mutation has been reported in 2 gastric cancers and 15 colorectal cancers [13]. While the E542K and the E545K mutations were not found in gastric cancer in the previous series, a large number of colorectal tumours did harbour these 2 mutations.
###end p 21
###begin p 22
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 172 179 172 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 375 382 375 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 408 413 408 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
PIK3CA mutation spectrum and their corresponding clinico-pathological features were listed in Table 1. We noted a higher tendency of high-level MSI in gastric cancers with PIK3CA mutations (3 in 4, 75%) than in those without (18 in 90, 20%). Moreover, though the overall incidence of KRAS mutation in the studied population was low (8 in 94), 2 of the 4 gastric cancers with PIK3CA mutation also harboured a KRAS mutation.
###end p 22
###begin p 23
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 97 104 97 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 227 234 227 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 409 410 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 417 419 417 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 435 442 435 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 620 627 620 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 703 720 703 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">Additional file 2</xref>
###xml 789 796 789 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
Since over-expression of PIK3CA has been reported in gastric cancer [11], we have also extracted PIK3CA expression data from our previous cDNA microarray study of these cases [14,15]. We have confirmed that expression level of PIK3CA was significantly higher in gastric cancers (n = 87, mean = 0.099, SD = 0.428) when compared with non-neoplastic gastric mucosae (n = 22, mean = -0.418, SD = 0.426; Student's t-Test, p < 0.001). Using PIK3CA expression level as a continuous variable for SAM analysis [17], we found 2910 cDNA clones (corresponding to about 2546 unique genes) whose expression associated positively with PIK3CA expression (median number of false significant = 0.372, Delta = 1.107) [see Additional file 2]. Interestingly, no gene was found to be negatively associated with PIK3CA expression.
###end p 23
###begin title 24
Discussion
###end title 24
###begin p 25
###xml 48 55 48 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 181 188 181 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 225 232 225 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 430 436 430 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 512 519 512 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 717 719 717 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 880 882 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1122 1127 1122 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 1260 1262 1260 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1263 1265 1263 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1420 1422 1420 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1464 1471 1464 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
In this study, we have reported the presence of PIK3CA gene mutation in 4.3% of gastric cancer. A high tendency (3 in 4) of mismatch repair deficiency was noted in cases harbouring PIK3CA mutation. Though the small number of PIK3CA mutations in our study may not justify statistical claim of significance; suggestion of such, despite of its not being mentioned by the authors, can be found from a previous study in CRC by Samuels et al.. From their study of 33 MSI and 201 microsatellite stable (MSS) CRC cases, PIK3CA mutation was present in 48% of the MSI tumours, but only in 29% of the MSS tumours. A significant association would have been revealed if statistical analysis had been applied (Fisher's exact test, p = 0.014) [13]. Gastrointestinal tract cancers with MSI are known to have a different molecular pathway of tumour evolution compared with their MSS counterparts [19,20]. This can be attributed to their propensity for frameshift mutations in repeat sequences, resulting in selective disruption of genes with such sequences within their coding regions. With 2 poly-adenine tracts within its coding region, PTEN can be inactivated through frameshift mutations in MSI CRC, resulting in the selective targeting of the PI3K-AKT signalling pathway [21,22]. It is also known that mismatch repair deficiency would lead to an elevated rate of missense mutation due to impaired single nucleotide mismatch repair [23]. Thus, the observed higher incidence of PIK3CA missense mutation in MSI colorectal and gastric cancers suggests yet another mechanism for the activation of the PI3K-AKT signalling pathway through mismatch repair deficiency.
###end p 25
###begin p 26
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 70 77 70 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 267 273 267 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 311 318 311 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1057 1062 1057 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 1091 1096 1091 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1128 1130 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1131 1133 1131 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1323 1328 1323 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 1366 1371 1366 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1382 1384 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1653 1655 1653 1655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Our data also showed a higher tendency of KRAS mutation in cases with PIK3CA mutations (2 in 4) than in those without (6 in 90). Yet again due to the low incidence of both mutations in our samples, statistical significance may not be claimed. In the study by Samuels et al., some of the colorectal tumours with PIK3CA mutation also harboured KRAS or BRAF mutation [13]. The PI3K-AKT pathway is known to have a close association with the RAS-MEKK signalling pathway [8]. Constitutively active RAS can interact with the catalytic subunit of PI3K and lead to its activation. Ras-dependent PI3K activation contributes to the transforming phenotype by mediating anchorage-independent growth, cytoskeletal reorganisation and apoptosis evasion. It has been observed that genes involved in the same signalling pathway may manifest mutations in cancer cells in a mutually exclusive manner, presumably due to the lack of selective growth advantage in having a second hit in the already altered pathway. A prominent example is the mutually exclusive occurrence of the BRAF hotspot mutation (V600E) and KRAS mutations in colorectal cancer [24,25]. However, there exist other examples of alterations in multiple components of the same signalling pathway that may lead to a multi-level modulation of its activity. For example, non-V600E BRAF mutations tend to occur together with KRAS mutations [26], and inactivation of the secreted frizzled-related proteins (antagonists of WNT) by promoter methylation frequently coincides with mutations in the Adenomatous Polyposis Coli gene to achieve multi-level activation of the WNT signalling pathway in colorectal cancers [27]. Whether PIK3CA functions independently from RAS, or acts synergistically with RAS to produce additive effects on the activation of the same pathway awaits further clarification.
###end p 26
###begin p 27
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 279 285 279 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 508 525 508 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">Additional file 2</xref>
###xml 571 577 571 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
###xml 844 851 844 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
By extracting data from microarray, we have confirmed the up-regulation of PIK3CA expression in gastric cancer tissues compared with the non-neoplastic gastric mucosae and identified a large number of genes that showed a significant positive correlation in expression level with PIK3CA. These genes participate in diverse cellular processes with 177 as putative cell cycle-regulated genes [28] and 126 mapped to genes with known functions in cell cycle regulation, cell proliferation or DNA replication [see Additional file 2]. While some of these genes maybe induced by PIK3CA, others maybe co-ordinately regulated by common upstream signals. Expression data set at one point was limited in differentiating the above cause and consequence, yet it certainly revealed the complexity of the carcinogenic process and the intricate relationship of PIK3CA signalling with other cellular processes.
###end p 27
###begin p 28
###xml 46 53 46 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 139 153 139 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Samuel et al. </italic>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
Contrary to our expectation, the incidence of PIK3CA mutation found in the current study (4%) is much lower compared with that observed by Samuel et al. (25%) [13]. The reason for discrepancy may simply be a result of sample bias as the previous study involved only a small number of gastric cancers (n = 12). However, ethnic differences can also be another possibility. The diverse pathological spectrum and aetiological factors of gastric cancers in different geographical locations may be paralleled by differences in molecular pathway of tumour development. Since our current study is only based on a Chinese population with an intermediate gastric cancer incidence, further studies involving patients from different ethnic groups will be able to address this possibility.
###end p 28
###begin title 29
Conclusion
###end title 29
###begin p 30
###xml 53 60 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 119 126 119 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 230 237 230 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 385 392 385 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
Large-scale screening of gastric adenocarcinomas for PIK3CA mutations revealed a mutation incidence of 4.3%. Increased PIK3CA expression level was observed in gastric tumours compared with non-neoplastic mucosae. This increase in PIK3CA level was associated with the elevated expression of a large number of genes, which may constitute the upstream regulators or downstream targets of PIK3CA along the PI3K signalling pathway.
###end p 30
###begin title 31
Competing interests
###end title 31
###begin p 32
The author(s) declare that they have no competing interests.
###end p 32
###begin title 33
Authors' contributions
###end title 33
###begin p 34
VSWL carried out the molecular analysis, performed data analysis and drafted the manuscript. CWW, TLC, WZ assisted in the molecular analysis. KMC provided the clinical data. ASWC assisted in data analysis and edited the manuscript. SS and XC participated in the microarray study and data analysis. STY and SYL conceived of the study, participated in its design, coordination and data analysis, and edited the manuscript. All authors read and approved the final manuscript.
###end p 34
###begin title 35
Pre-publication history
###end title 35
###begin p 36
The pre-publication history for this paper can be accessed here:
###end p 36
###begin p 37

###end p 37
###begin title 38
Supplementary Material
###end title 38
###begin title 39
Additional File 1
###end title 39
###begin p 40
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 107 114 107 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
Primers and PCR conditions used for PIK3CA sequencing. Conditions for PCR and sequences of primers used in PIK3CA sequencing
###end p 40
###begin p 41
Click here for file
###end p 41
###begin title 42
Additional File 2
###end title 42
###begin p 43
###xml 43 50 43 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 146 153 146 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 588 595 588 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
SAM significant genes list associated with PIK3CA expression. SAM detected 2910 genes whose expression levels were positively associated with the PIK3CA expression level. Gene expression data were extracted from the microarray database containing 126 samples (90 gastric adenocarcinomas, 14 lymph node metastasis and 22 non-tumour gastric mucosae) based on a 3-fold signal above background ratio for either channel and with 80% good data [14]. Gene expression data from 20,336 cDNA clones satisfied this selection criteria and were extracted, which included a cDNA clone corresponding to PIK3CA (IMAGE clone number 345430, GenBank accession no. W72473). Expression value of this clone was imputed as a quantitative variable for SAM analysis. The missing values in the dataset were estimated by a K-nearest neighbours impute algorithm using 10 nearest neighbour followed by 5000 permutations in the SAM analysis.
###end p 43
###begin p 44
Click here for file
###end p 44
###begin title 45
Acknowledgements
###end title 45
###begin p 46
This work was supported by the Research Grants Council of the Hong Kong Special Administrative Region, HKU 7313/02M.
###end p 46
###begin article-title 47
###xml 49 54 <span type="species:ncbi:9606">human</span>
The phosphatidylinositol 3-Kinase AKT pathway in human cancer
###end article-title 47
###begin article-title 48
PTEN: from pathology to biology
###end article-title 48
###begin article-title 49
PIK3CA as an oncogene in cervical cancer
###end article-title 49
###begin article-title 50
PIK3CA is implicated as an oncogene in ovarian cancer
###end article-title 50
###begin article-title 51
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma
###end article-title 51
###begin article-title 52
AKT plays a central role in tumorigenesis
###end article-title 52
###begin article-title 53
###xml 47 52 <span type="species:ncbi:9606">human</span>
AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells
###end article-title 53
###begin article-title 54
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer
###end article-title 54
###begin article-title 55
###xml 105 110 <span type="species:ncbi:9606">human</span>
Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma
###end article-title 55
###begin article-title 56
Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis
###end article-title 56
###begin article-title 57
Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma
###end article-title 57
###begin article-title 58
###xml 46 51 <span type="species:ncbi:9606">human</span>
###xml 113 118 <span type="species:ncbi:9606">human</span>
Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma
###end article-title 58
###begin article-title 59
###xml 50 55 <span type="species:ncbi:9606">Human</span>
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
###end article-title 59
###begin article-title 60
###xml 41 46 <span type="species:ncbi:9606">human</span>
Variation in gene expression patterns in human gastric cancers
###end article-title 60
###begin article-title 61
Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis
###end article-title 61
###begin article-title 62
Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability
###end article-title 62
###begin article-title 63
Significance analysis of microarrays applied to the ionizing radiation response
###end article-title 63
###begin article-title 64
Missing value estimation methods for DNA microarrays
###end article-title 64
###begin article-title 65
Deficient DNA mismatch repair: a common etiologic factor for colon cancer
###end article-title 65
###begin article-title 66
Tumors with microsatellite instability: many mutations, targets and paradoxes
###end article-title 66
###begin article-title 67
Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis
###end article-title 67
###begin article-title 68
PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers
###end article-title 68
###begin article-title 69
Differences in the spectrum of spontaneous mutations in the hprt gene between tumor cells of the microsatellite mutator phenotype
###end article-title 69
###begin article-title 70
###xml 30 35 <span type="species:ncbi:9606">human</span>
Mutations of the BRAF gene in human cancer
###end article-title 70
###begin article-title 71
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status
###end article-title 71
###begin article-title 72
Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia
###end article-title 72
###begin article-title 73
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer
###end article-title 73
###begin article-title 74
###xml 54 59 <span type="species:ncbi:9606">human</span>
Identification of genes periodically expressed in the human cell cycle and their expression in tumors
###end article-title 74
###begin title 75
Figures and Tables
###end title 75
###begin p 76
###xml 0 38 0 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative sequence chromatogram. </bold>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
Representative sequence chromatogram. (a) Sequence chromatogram from a case of gastric cancer with H1047R (A3140G) mutation within exon 20 of PIK3CA. Site of mutation is denoted by the red arrow. (b) Sequence chromatogram of the corresponding normal mucosa from the same case showing the absence of mutation (red arrow), and thus confirming the somatic nature of the mutation.
###end p 76
###begin p 77
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
Spectrum of PIK3CA mutations in gastric adenocarcinoma
###end p 77
###begin p 78
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aNucleotide change at the position within coding sequence, where position 1 corresponds to the first position of the start codon
###end p 78
###begin p 79
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bHigh, high level of MSI; Stable, microsatellite stable
###end p 79
###begin p 80
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
cAnalysis of KRAS mutations have been performed and reported previously [16]
###end p 80
###begin p 81
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
dIM, the presence of intestinal metaplasia at tumour edge; 1, present; 0, absent
###end p 81

